HC Wainwright Downgrades Shattuck Labs (NASDAQ:STTK) to Neutral

Shattuck Labs (NASDAQ:STTK) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “neutral” rating in a report released on Tuesday, Marketbeat reports.

Other equities research analysts have also recently issued research reports about the company. Citigroup reduced their price objective on Shattuck Labs from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Shattuck Labs in a research note on Friday, August 2nd. Finally, BTIG Research lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Monday, June 17th.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $1.25 on Tuesday. The stock has a market capitalization of $59.44 million, a price-to-earnings ratio of -0.65 and a beta of 1.72. Shattuck Labs has a 52-week low of $1.18 and a 52-week high of $11.76. The stock’s 50 day moving average price is $3.49 and its two-hundred day moving average price is $6.04.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The company’s quarterly revenue was up 704.5% compared to the same quarter last year. On average, equities research analysts forecast that Shattuck Labs will post -1.72 EPS for the current year.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors have recently bought and sold shares of STTK. SG Americas Securities LLC lifted its stake in Shattuck Labs by 4.8% during the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock valued at $352,000 after acquiring an additional 1,788 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Shattuck Labs by 8.5% during the second quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock valued at $266,000 after purchasing an additional 5,397 shares in the last quarter. American Century Companies Inc. boosted its holdings in Shattuck Labs by 25.4% during the second quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock worth $183,000 after purchasing an additional 9,608 shares during the last quarter. Cannon Global Investment Management LLC bought a new stake in Shattuck Labs in the 1st quarter worth about $91,000. Finally, Virtu Financial LLC purchased a new stake in Shattuck Labs in the 1st quarter valued at about $113,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.